DynamiCare Health is a digital therapeutics and coaching company that provides behavioral health services to help individuals overcome addiction to drugs, alcohol, and tobacco through motivation, accountability, and contingency management techniques. The company partners with treatment programs, academic research institutions, and health plans including Horizon Blue Cross Blue Shield of New Jersey, Vermont Medicaid, Johns Hopkins University School of Medicine, and University of Vermont.

Absco Therapeutics is a biopharmaceutical company developing drug delivery technologies using thermogelling polymers that transform from liquid to solid at body temperature to create controlled-release depots for immune-modulating therapies. The company's lead program, ABS005, is a non-surgical treatment candidate for cervical intraepithelial neoplasia (CIN2/3) that combines a clinically validated drug with the company's polymer system for sustained intralesional delivery.

Accelerated Muscle Biotechnologies (AMB) is a contract research organization that provides access and support to muscle researchers, specializing in physiological structure-function characterization through muscle functional assays and small-angle X-ray diffraction. The company operates laboratories in Boston and Hamburg, conducting muscle X-ray diffraction experiments and muscle fiber experimentation for clients and collaboration partners at synchrotron facilities worldwide.

INSUFFICIENT The page content provided is primarily a contact page with header navigation, company name, tagline, and contact details, but lacks substantive information about the company's actual products or services beyond the vague tagline "Accelerating early-stage drug discovery."

Aldatu Biosciences develops molecular diagnostic assays using its proprietary PANDAA (Pan Degenerate Amplification and Adaptation) platform to detect infectious diseases including SARS-CoV-2, HIV drug resistance, and viral hemorrhagic fevers through RT-PCR technology. The company's technology is designed to detect pathogens in genomically variable regions without requiring assay redesign when new viral variants emerge.

Alzheon is a clinical-stage biopharmaceutical company developing small-molecule treatments for neurodegenerative disorders, with a Phase 3 program for Alzheimer's disease based on an anti-aggregation mechanism. The company's lead program, valiltramiprosate (ALZ-801), is an oral anti-amyloid oligomer inhibitor being tested in early Alzheimer's disease and mild cognitive impairment, while a second clinical-stage program (ALZ-507) targets Alzheimer's disease prevention.

Telehealth platform (American Well Corporation). HQ Boston, MA. Blue Heron Capital exited investment (invested 2018, exited via IPO).

The Amyloidosis Research Consortium (ARC) is a nonprofit organization that provides patient support, education, and resources for people with amyloidosis while funding and coordinating research initiatives to advance treatment options. ARC offers webinars, clinical trial information, a patient-provider communication tool called My Amyloidosis Pathfinder, and guidance specific to different amyloidosis types including AL, hereditary ATTR, and wild-type ATTR amyloidosis.

Aphios is a biotechnology company developing pharmaceutical therapeutics and enabling technology platforms focused on oncology, infectious disease, and central nervous system disorders using nanotechnology drug delivery and green manufacturing processes. The company operates through multiple subsidiaries including Aphios Pharma LLC, which develops cannabinoid-based drugs for chronic pain and anxiety, and Zindol LLC, which is developing a ginger extract therapy for chemotherapy-induced nausea ...